[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Affiliated Hospital of Qinghai University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":153},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,67,94,122],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100644315","electroacupuncture-for-preventing-chemotherapy-induced-peripheral-neuropathy-in-patients-with-early-stage-cancer-100644315",false,"NCT07663396","Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Early-stage Cancer","Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Early-stage Cancer: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Pathological and imaging examinations confirmed the diagnosis of early-stage cancer(I-III stage), including: breast cancer, gastric cancer, intestinal cancer, non-small cell lung cancer or ovarian cancer.\n* Eastern Cooperative Oncology Group Performance Status of 0 or 1.\n* Scheduled to receive chemotherapy containing a taxane, utidelone, or oxaliplatin, with no significant pre-existing neurological symptoms prior to chemotherapy. Specific regimens include: Colorectal cancer: Oxaliplatin-containing regimen. Gastric cancer: Oxaliplatin-containing or taxane-containing regimen. Breast cancer: Taxane-containing or utidelone-containing regimen. Non small cell lung cancer or Ovarian cancer: Taxane-containing regimen.\n* No history of acupuncture treatment within one month prior to study initiation.\n* Adequate major organ function, meeting the following laboratory criteria: Hematology: Absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL; Platelet count ≥ 100 × 10\\^9\u002FL; White blood cell count 3.5 - 9.5 × 10\\^9\u002FL; Hemoglobin ≥ 100 g\u002FL. Hepatic Function: Total bilirubin ≤ 1.5 × upper limit of normal; Aspartate aminotransferase and alanine aminotransferase ≤ 3 × ULN; Serum bilirubin concentration \\\u003C 1.5 mg\u002FdL; Serum albumin \\> 2.5 g\u002FdL. Renal Function: Serum creatinine ≤ 1.5 × ULN, OR calculated creatinine clearance ≥ 50 mL\u002Fmin (using the Cockcroft-Gault formula). Coagulation: International normalized ratio ≤ 1.5, AND activated partial thromboplastin time ≤ 1.5 × ULN.\n* Willing to receive acupuncture intervention and undergo subsequent follow-up assessments.\n* Voluntarily agree to participate in the study and sign an informed consent form.\n\nExclusion Criteria:\n\n* Patients with advanced cancer.\n* Pre-existing peripheral neuropathy prior to the initiation of chemotherapy.\n* Severe impairment of major organ function, rendering the patient unable to tolerate standard-dose chemotherapy.\n* Presence of active skin infection or other conditions unsuitable for acupuncture treatment.\n* Coexisting underlying diseases associated with peripheral neuropathy, such as diabetes mellitus, Guillain-Barré syndrome, or chronic inflammatory demyelinating polyradiculoneuropathy.\n* Current use of medications for neuropathic pain (e.g., gabapentin, pregabalin).\n* Pregnant or lactating patients.\n* Presence of dermatological conditions, as assessed by the clinician, that may interfere with the study procedures or outcomes.\n* Patients with active brain metastases.\n* Patients with a history of implanted cardiac pacemakers or defibrillators, or a history of epilepsy.","ALL","18 Years",{"count":19,"type":20},278,"ESTIMATED","INTERVENTIONAL",[23],"NA","This randomized controlled clinical trial aims to clarify the clinical efficacy and safety of electroacupuncture combined with thumbtack needle for the prevention of chemotherapy-induced peripheral neuropathy(CIPN), and to provide high-level evidence-based medicine for the prevention of CIPN in patients with early stage cancer. At the same time, the effects of electroacupuncture on the median nerve, tibial nerve, sural nerve sensory conduction velocity and sensory nerve action potential, as well as on the median nerve and tibial nerve motor conduction velocity will be analyzed.",[26,27,28,29],"Electroacupuncture","Chemotherapy","Peripheral Neuropathy","Early Stage Cancer",[31,27,32,33],"electroacupuncture","Peripheral neuropathy","early stage cancer","NOT_YET_RECRUITING","2026-06-17",{"date":37,"type":38},"2026-06-23","ACTUAL",{"date":40,"type":20},"2026-05-25",{"date":42,"type":20},"2029-07-31",{"name":44,"class":45},"Affiliated Hospital of Qinghai University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":65,"leadSponsor":66,"locationsCount":46},"100642496","electroacupuncture-for-preventing-chemotherapy-induced-peripheral-neuropathy-in-patients-with-advanced-cancer-100642496","NCT07644533","Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Advanced Cancer","Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Advanced Cancer: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Pathological and imaging examinations confirmed the diagnosis of advanced cancer(IV stage), including: breast cancer, gastric cancer, intestinal cancer, non-small cell lung cancer or ovarian cancer;\n* Eastern Cooperative Oncology Group Performance Status of 0 or 1.\n* Scheduled to receive chemotherapy containing a taxane, utidelone, or oxaliplatin, with no significant pre-existing neurological symptoms prior to chemotherapy. Specific regimens include: Colorectal cancer: Oxaliplatin-containing regimen. Gastric cancer: Oxaliplatin-containing or taxane-containing regimen. Breast cancer: Taxane-containing or utidelone-containing regimen. NSCLC or Ovarian cancer: Taxane-containing regimen.\n* No history of acupuncture treatment within one month prior to study initiation.\n* Adequate major organ function, meeting the following laboratory criteria: Hematology: Absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL; Platelet count ≥ 100 × 10\\^9\u002FL; White blood cell count 3.5 - 9.5 × 10\\^9\u002FL; Hemoglobin ≥ 100 g\u002FL. Hepatic Function: Total bilirubin ≤ 1.5 × upper limit of normal (ULN); Aspartate aminotransferase and alanine aminotransferase ≤ 3 × ULN; Serum bilirubin concentration \\\u003C 1.5 mg\u002FdL; Serum albumin \\> 2.5 g\u002FdL. Renal Function: Serum creatinine ≤ 1.5 × ULN, OR calculated creatinine clearance ≥ 50 mL\u002Fmin (using the Cockcroft-Gault formula). Coagulation: International normalized ratio ≤ 1.5, AND activated partial thromboplastin time ≤ 1.5 × ULN.\n* Willing to receive acupuncture intervention and undergo subsequent follow-up assessments.\n* Voluntarily agree to participate in the study and sign an informed consent form.\n\nExclusion Criteria:\n\n* Patients with early-stage cancer.\n* Pre-existing peripheral neuropathy prior to the initiation of chemotherapy.\n* Severe impairment of major organ function, rendering the patient unable to tolerate standard-dose chemotherapy.\n* Presence of active skin infection or other conditions unsuitable for acupuncture treatment.\n* Coexisting underlying diseases associated with peripheral neuropathy, such as diabetes mellitus, Guillain-Barré syndrome, or chronic inflammatory demyelinating polyradiculoneuropathy.\n* Current use of medications for neuropathic pain (e.g., gabapentin, pregabalin).\n* Pregnant or lactating patients.\n* Presence of dermatological conditions, as assessed by the clinician, that may interfere with the study procedures or outcomes.\n* Patients with active brain metastases.\n* Patients with a history of implanted cardiac pacemakers or defibrillators, or a history of epilepsy.",{"count":55,"type":20},264,[23],"This randomized controlled clinical trial aims to clarify the clinical efficacy and safety of electroacupuncture combined with thumbtack needle for the prevention of chemotherapy-induced peripheral neuropathy(CIPN), and to provide high-level evidence-based medicine for the prevention of CIPN in patients with advanced cancer. At the same time, the effects of electroacupuncture on the median nerve, tibial nerve, sural nerve sensory conduction velocity and sensory nerve action potential, as well as on the median nerve and tibial nerve motor conduction velocity will be analyzed.",[26,27,59,28],"Advanced Cancer",[27,59,32,26],"2026-06-10",{"date":63,"type":38},"2026-06-12",{"date":40,"type":20},{"date":42,"type":20},{"name":44,"class":45},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":21,"phases":75,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":46},"100608957","phase-3-olanzapine-plus-metoclopramide-for-the-prevention-of-opioid-induced-nausea-and-vomiting-100608957","NCT07208305","Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting","Inclusion criteria\n\n1. Patients with malignant tumors diagnosed by pathology or histology;\n2. Patients diagnosed with locally advanced or advanced stages by imaging;\n3. Age ≥ 18 years old;\n4. The eastern cooperative oncology group (ECOG) performance status of 0-3;\n5. The expected survival period shall be no less than 4 weeks;\n6. Moderate or severe cancer pain with a Numerical Rating Scale (NRS) score of ≥ 4 points;\n7. Be able to take oral medication;\n8. Initial treatment with potent opioid painkillers (such as morphine, oxycodone, fentanyl, etc.);\n9. No systemic chemotherapy or radiotherapy was received within one month prior to selection, and no drugs that may induce nausea and vomiting were used.\n10. There were no gastrointestinal discomforts such as nausea or vomiting at the time of selection, and no intestinal obstruction.\n11. Possess normal comprehension and communication skills, be capable of completing research evaluations and following research procedures.\n\nExclusion criteria\n\n1. Diabetic patients with a clear diagnosis and poorly controlled blood sugar levels;\n2. There are symptoms of nausea or vomiting;\n3. Symptomatic intracranial diseases, such as brain metastases or leptomeningeal metastasis;\n4. Received chemotherapy drug treatment within one week before the trial medication or during the trial period;\n5. Receive radiotherapy for the head, abdomen or pelvic cavity within one week before the trial or during the trial;\n6. New drugs with emetic or antiemetic effects have been used within 48 hours before the start of the trial;\n7. Patients with severe electrolyte imbalance, abnormal kidney or liver function;\n8. Patients with gastrointestinal bleeding;\n9. Pregnant or lactating women;\n10. Patients diagnosed with breast cancer;\n11. Those whose electrocardiogram examination indicates heart disease or prolonged QTc interval;\n12. There is a history of allergy or contraindications to olanzapine or metoclopramide.",{"count":74,"type":20},222,[76],"PHASE3","The goal of this clinical trial is to evaluate the efficacy and safety of olanzapine plus metoclopramide in preventing opioid-induced nausea and vomiting (OINV) in adult patients with advanced cancer who are initiating strong opioid therapy. The main questions it aims to answer are: (1) Does the combination of olanzapine and metoclopramide reduce the incidence of OINV? (2)What adverse events do participants experience when taking the combination of olanzapine and metoclopramide? Researchers will compare the olanzapine-metoclopramide combination to a no prophylactic treatment control group to determine whether the combination is effective in preventing OINV.\n\nParticipants will: Take olanzapine (2.5 mg\u002Fday ) and metoclopramide (10 mg three times daily) or receive no prophylaxis for 7 days; Through follow-up, nausea, vomiting, the time of the first attack of nausea and vomiting, the duration of nausea and vomiting, the use of strong opioids and adverse events were evaluated and recorded, as well as the pain score (using NRS) and quality of life (EQ-5D-5L) of the patients were evaluated at baseline and on day 7.",[79,80],"Nausea","Vomiting",[82,83,84,79,80],"Olanzapine","Metoclopramide","Opioid","RECRUITING","2026-04-23",{"date":88,"type":38},"2026-04-27",{"date":90,"type":38},"2026-02-03",{"date":92,"type":20},"2027-12-30",{"name":44,"class":45},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":101,"minAge":17,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":21,"phases":105,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":46},"100575488","electroacupuncture-treatment-of-peripheral-neuropathy-after-taxane-chemotherapy-for-breast-cancer-100575488","NCT06772935","Electroacupuncture Treatment of Peripheral Neuropathy After Taxane Chemotherapy for Breast Cancer","CIPN","Inclusion Criteria:\n\n* Breast cancer patients diagnosed by pathology;\n\n  * EOOG score is 0 or 1;\n\n    * The age range for enrollment is between 18 and 75 years old; ④ Accept chemotherapy regimens based on taxane drugs (alone or in combination);\n\n      ⑤ Previously received taxane chemotherapy for more than 6 months;\n\n      ⑥ According to the National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) 5.0, reporting CIPN symptoms of grade 1 or higher for more than 2 weeks;\n\n      ⑦ Voluntarily participate in this clinical trial and sign the informed consent form;\n      * Accept regular follow-up visits; ⑨ There is complete pathological data available.\n\nExclusion Criteria:\n\n* Non breast cancer patients;\n\n  * Received electroacupuncture treatment within 6 months prior to the start of the study;\n\n    * Patients who experience intolerable toxic side effects during standard dose chemotherapy and terminate the chemotherapy cycle;\n\n      * Prior to enrollment, there was a history of peripheral neuropathy;\n\n        * Unstable heart disease or myocardial infarction within the first 6 months of the study;\n\n          ⑥ Active skin diseases or surface skin ulcers or infections that cannot tolerate electroacupuncture treatment;\n\n          ⑦ Uncontrolled epilepsy patients with uncontrolled seizures;\n\n          ⑧ Merge with other malignant tumor patients;\n\n          ⑨ Pregnancy and lactation period;\n\n          ⑩ Refusal to join clinical trial patients","FEMALE","75 Years",{"count":104,"type":20},162,[23],"Electroacupuncture treatment of peripheral neuropathy after taxane chemotherapy for breast cancer",[108],"Breast Cancer",[110,31,111,112,113],"breast cancer","taxanes","SNPs","chemotherapy","2025-01-12",{"date":116,"type":38},"2025-01-14",{"date":118,"type":20},"2025-06-01",{"date":120,"type":20},"2027-12-31",{"name":44,"class":45},{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":129,"sex":16,"minAge":17,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":21,"phases":133,"briefSummary":134,"conditions":135,"keywords":140,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":152,"locationsCount":46},"100562361","electroacupuncture-combined-with-self-administered-acupressure-for-the-prevention-of-capecitabine-associated-hand-foot-syndrome-100562361","NCT06602167","Electroacupuncture Combined With Self-administered Acupressure for the Prevention of Capecitabine-Associated Hand-Foot Syndrome","Electroacupuncture Combined With Self-administered Acupressure for the Prevention of Capecitabine-Associated Hand-Foot Syndrome: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Sign a written informed consent form;\n2. Male or female ≥ 18 years old;\n3. Patients with gastrointestinal cancer or breast cancer who are diagnosed with cancer by pathology will receive capecitabine treatment for the first time according to the label;\n4. The performance status of the Eastern Cancer Collaboration Group is 0-2;\n5. Palliative or adjuvant chemotherapy with capecitabine (combination or monotherapy, minimum daily total dose of capecitabine 2000 mg\u002Fm\\^2);\n6. Expected lifespan ≥ 3 months;\n7. Laboratory requirements: platelet count ≥ 100 × 10\\^9\u002FL, white blood cell count\\>3.0 × 10\\^9\u002FL, hemoglobin ≥ 10.0 g\u002FdL, normal liver and kidney function;\n8. Adequate contraception.\n\nExclusion Criteria:\n\n1. Previous use of capecitabine or liposome doxorubicin or any other tyrosine kinase inhibitor that may induce HFS (such as sorafenib, sunitinib, and apatinib) for chemotherapy;\n2. The initial dose of capecitabine is less than 800mg\u002Fm\\^2;\n3. Radiation therapy or surgery should be performed within 4 weeks before the start of treatment;\n4. Skin diseases that may interfere with clinical trial results;\n5. Known drug\u002Falcohol abuse;\n6. Pregnant women or lactating patients;\n7. Participate in another clinical trial and the patient has received the investigational drug within the last 30 days prior to the start of treatment (i.e. follow-up in the previous trial was not exclusive);\n8. Known patients who are afraid of electroacupuncture stimulation or allergic to stainless steel needles or any component of capecitabine;\n9. Receive any acupuncture and moxibustion treatment ,there is lymphedema in the area stimulated by acupuncture;\n10. Patients with any chemotherapy- or radiotherapy-related toxicities that have not subsided to grade 2 or lower will be excluded, except for stable sensory neuropathy.\n11. Any unresolved skin toxicity caused by previous chemotherapy or radiotherapy, except for hair loss, will also be grounds for exclusion.",true,"85 Years",{"count":132,"type":20},220,[23],"This study hypothesizes that electroacupuncture combined with self-administered acupressure plus doctor-prescribed treatment is effective in preventing Hand-Foot Syndrome (HFS) caused by capecitabine. It aims to explore the effectiveness of this combined approach in preventing HFS in patients with malignant tumors undergoing oral capecitabine treatment. Further exploration of prevention and treatment methods may enhance the quality of life for patients during the treatment process.",[136,137,26,138,108,139],"Capecitabine","Hand-foot Syndrome","Self-administered Acupressure","Gastrointestinal Cancers",[31,141,142,143,144,145],"capecitabine","self-administered acupressure","Hand-foot syndrome","Breast cancer","Gastrointestinal cancers","2024-12-09",{"date":148,"type":38},"2024-12-12",{"date":150,"type":38},"2024-10-08",{"date":120,"type":20},{"name":44,"class":45},""]